Gå direkte til indholdet

Seglcellesygdom (børn)

Anæmibehandling

Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. (åbner nyt vindue)

Ambrose EE, Latham TS, Songoro P, Charles M, Lane AC, Stuber SE, Makubi AN, Ware RE, Smart LR

Kilde‎: Lancet Haematol. 2023 ;10(4):e261-71.

Indekseret‎: PubMed 36870358

DOI‎: 10.1016/S2352-3026(22)00405-7

https://pubmed.ncbi.nlm.nih.gov/36870358/ (åbner nyt vindue)

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (åbner nyt vindue)

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Kilde‎: Acta Haematol 1995;94(3):128-34.

Indekseret‎: PubMed 7502628

https://www.ncbi.nlm.nih.gov/pubmed/7502628 (åbner nyt vindue)

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (åbner nyt vindue)

Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, Taylor JG 6th, Machado RF, Heller T, Castro O, Gladwin MT.

Kilde‎: Haematologica 2006;91(8):1076-83.

Indekseret‎: PubMed 16885048

https://www.ncbi.nlm.nih.gov/pubmed/16885048 (åbner nyt vindue)

Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (åbner nyt vindue)

Tan TL, Ahmad H, Jhavar R, Patel R, Harrison C, Oteng-Ntim E.

Kilde‎: J Obstet Gynaecol 2007;27(1):82-3.

Indekseret‎: PubMed 17365469

DOI‎: 10.1080/01443610601062739

https://www.ncbi.nlm.nih.gov/pubmed/17365469 (åbner nyt vindue)